Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > MediPharm Labs Revenues Continue To Decline, Posts Negative
View:
Post by AwareInvestor on Aug 16, 2021 8:53am

MediPharm Labs Revenues Continue To Decline, Posts Negative

Medipharm Labs this morning continued to show its desperate need for effective leadership. The company posted yet another quarter of declining revenues and negative margins, posting just $5.1 million in revenues for the second quarter along with a loss of $11.8 million.
Comment by Starkicker on Aug 16, 2021 9:40am
Brutal. The first line says it all.
Comment by BDHG01 on Aug 16, 2021 10:06am
They had some write-downs that contributed to decreased profit this quarter, but still managed to post a net loss that improved from last quarter, or compared to the disastrous Q4 2020.  I think these numbers show a company pulling out of a hole they largely created themselves by betting the 'Pharm' (if you will) on pivoting away from the domestic B2B market and instead doubling down ...more  
Comment by corvette67 on Aug 16, 2021 11:35am
Maybe someone will buy out this POS. On the bright side, nobody should worry about $.70 warrants being exercised. GLTA
Comment by jayc1 on Aug 22, 2021 1:56pm
If those .70 warrants are not exercised we will see dilution at much lower price. So i hope we can get to .70 in near future.
Comment by mdjbrown on Aug 23, 2021 12:02am
lol jc1 You have ants in yur pants or something Warrants dont expire until March 2023..... so lots of time yet to capitalize on those cheapies once international revenues multiply, and the shareprice starts to reflect the improvements. Dont forget, the when in May, go away crowd will be coming back to the market in another month or less, and if Q3 results show improvement, its anyones guess as ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities